Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | How the treatment and management of ALL changes with age

Emily Curran • 28 Sep 2022
SOHO 2022
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

In this video, Emily Curran, MD, The University of Cincinnati, Cincinnati, OH, comments on how the treatment and management of acute lymphoblastic leukemia (ALL) changes with age. Dr Curran first explains the role of pediatric-based regimens in the treatment of ALL, and then goes on to highlight the importance of incorporating novel immunotherapies when treating older patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Emily Curran

1:20
The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALL
Emily Curran • 28 Sep 2022
2:04
Treatment approaches to Ph-like ALL: challenges and future outlooks
Emily Curran • 28 Sep 2022
1:16
The biology of Ph-like ALL and challenges in this disease subtype
Emily Curran • 28 Sep 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals